Beacon Financial Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$872K Buy
754
+55
+8% +$64.9K 0.17% 162
2026
Q2
$838K Hold
699
– – 0.17% 165
2026
Q1
$643K Buy
699
+60
+9% +$60.8K 0.15% 185
2025
Q4
$687K Buy
639
+165
+35% +$158K 0.16% 168
2025
Q3
$362K Buy
474
+39
+9% +$29K 0.08% 256
2025
Q2
$339K Buy
435
+63
+17% +$49K 0.09% 259
2025
Q1
$307K Buy
372
+92
+33% +$76.6K 0.09% 240
2024
Q4
$216K Buy
280
+8
+3% +$6.62K 0.07% 273
2024
Q3
$241K Buy
272
+37
+16% +$33.3K 0.08% 253
2024
Q2
$212K Sell
235
-45
-16% -$36K 0.08% 263
2024
Q1
$218K Buy
+280
New +$199K 0.11% 224

Other funds holding LLY

Beacon Financial Advisory's LLY Position: Q3 2026 in Review

Beacon Financial Advisory increased its Eli Lilly (LLY) stake by 7.9% in Q3 2026, buying an estimated $64.9K and bringing the position to 754 shares worth $872K. The position accounts for 0.17% of the portfolio, ranked #162.

Beacon Financial Advisory first reported a position in LLY in Q1 2024 and has held it in 11 quarters since. 2,534 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Beacon Financial Advisory held 754 shares of Eli Lilly worth $872K as of Q3 2026.
  • Beacon Financial Advisory bought 55 Eli Lilly shares in Q3 2026, an estimated $64.9K.
  • Eli Lilly made up 0.17% of Beacon Financial Advisory's portfolio in Q3 2026, its #162 holding.
  • Beacon Financial Advisory first reported a position in Eli Lilly in Q1 2024 and has held it in 11 quarters since.
  • 2,534 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Beacon Financial Advisory's 13F filing for Q3 2026, filed 16 Oct 2026.